Get started

Financials · RCUS

Arcus Biosciences Inc. (RCUS) financials

For the twelve months ended Sep 30, 2026, Arcus Biosciences Inc. reported $100.00M of revenue and -$453.00M of net income.

Revenue, TTM
$100.00M
Revenue growth, YoY
-58.3%
Net income, TTM
-$453.00M
Net margin
-453.0%
Free cash flow, TTM
-$466.00M
EPS, diluted, TTM
-$3.62
Cash
$151.00M
Total debt
$102.00M
P/S
26.88
Market cap
$2.69B
Annual revenue$247.00M
FY2017FY2025
Annual net income-$353.00M
FY2016FY2025
Annual free cash flow-$484.00M
FY2016FY2025

RCUS revenue and earnings growth

RCUS revenueQ3 2026$9.00M

Quarter YoY
-65.4%
QoQ
-78.0%
FY YoY
-4.3%
5Y CAGR
+25.9%

RCUS revenue was $9.00M in fiscal Q3 2026 (ended Sep 30, 2026), down 65.4% from a year earlier and down 78.0% from the prior quarter. For the full fiscal 2025 it was $247.00M, down 4.3% from fiscal 2024. Compound annual growth was +25.9% over 5 years. It rose in 6 of the last 8 fiscal years.

RCUS net incomeQ3 2026-$128.00M

RCUS net income was -$128.00M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$135.00M a year earlier. For the full fiscal 2025 it was -$353.00M, compared with -$283.00M in fiscal 2024.

RCUS EPSQ3 2026-$1.00

RCUS diluted EPS was -$1.00 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.27 a year earlier. For the full fiscal 2025 it was -$3.29, compared with -$3.14 in fiscal 2024.

RCUS free cash flowQ3 2026-$88.00M

RCUS free cash flow was -$88.00M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$97.00M a year earlier. For the full fiscal 2025 it was -$484.00M, compared with -$176.00M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$247.00M$258.00M$117.00M$112.00M$383.00M$78.00M$15.00M$8.35M$1.41M-
Research and development$523.00M$448.00M$340.00M$288.00M$257.00M$159.00M$78.48M$49.65M$47.22M$14.25M
Selling, general and admin$110.00M$120.00M$117.00M$104.00M$72.00M$43.00M$25.23M$13.57M$7.64M$3.94M
Operating income-$386.00M-$330.00M-$340.00M-$280.00M$54.00M-$124.00M-$88.71M-$54.86M-$53.44M-$18.18M
Interest expense$8.00M$4.00M$2.00M$2.00M------
Pre-tax income-$353.00M-$282.00M-$301.00M-$266.00M$55.00M-$123.00M-$84.71M---
Income tax$0$1.00M$6.00M$1.00M$2.00M-----
Net income-$353.00M-$283.00M-$307.00M-$267.00M$53.00M-$123.00M-$84.71M-$49.59M-$53.08M-$17.97M
EPS, basic-$3.29-$3.14-$4.15-$3.71$0.76-$2.24-$1.93-$1.43-$29.03-$20.80
EPS, diluted-$3.29-$3.14-$4.15-$3.71$0.71-$2.24-$1.93-$1.43-$29.03-$20.80
Diluted shares107.4M90.1M74.0M72.0M74.0M54.8M43.8M34.6M1.8M863,983

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$222.00M$150.00M$127.00M$206.00M$148.00M$173.41M$57.94M$71.06M$98.43M$65.16M
Current assets$1.01B$1.02B$831.00M$1.07B$1.26B$735.82M$192.71M$258.95M$176.87M-
Total assets$1.14B$1.15B$1.09B$1.34B$1.59B$772.29M$203.11M$274.93M$190.49M-
Current liabilities$231.00M$226.00M$184.00M$193.00M$166.00M$121.67M$22.71M$16.93M$12.73M-
Total debt$99.00M$48.00M$0-------
Total liabilities----$750.45M$269.99M$39.27M$39.98M$36.62M-
Shareholders' equity$631.00M$485.00M$462.00M$657.00M$842.00M$502.00M$164.00M$234.94M-$72.33M-$19.99M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$482.00M-$170.00M-$306.00M$438.00M-$256.00M$111.00M-$73.46M-$43.00M-$25.06M-$12.94M
Capital expenditures$2.00M$6.00M$24.00M$6.00M$26.00M$3.00M$1.93M$3.74M$5.51M$4.10M
Free cash flow-$484.00M-$176.00M-$330.00M$432.00M-$282.00M$108.00M-$75.39M-$46.74M-$30.57M-$17.04M
Investing cash flow$66.00M-$84.00M$194.00M-$413.00M-$4.00M-$434.00M$59.21M-$113.44M-$49.07M-$38.86M
Financing cash flow$488.00M$277.00M$33.00M$33.00M$237.00M$439.00M$1.12M$129.07M$107.40M$70.10M
Share repurchases------$94.0K$0--
Stock-based compensation$60.00M$76.00M$73.00M$65.00M$55.00M$22.00M$8.98M$3.87M$495.0K$90.0K
Depreciation and amortization$10.00M$10.00M$8.00M$6.00M$4.00M$3.00M$3.58M$3.66M$2.61M$1.31M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-4.3%120.5%4.5%-70.8%391.0%420.0%79.6%491.2%--
Operating margin-156.3%-127.9%-290.6%-250.0%14.1%-159.0%-591.4%-656.8%-3782.1%-
Net margin-142.9%-109.7%-262.4%-238.4%13.8%-157.7%-564.7%-593.7%-3756.7%-
Free cash flow margin-196.0%-68.2%-282.1%385.7%-73.6%138.5%-502.6%-559.5%-2163.7%-
Return on equity-55.9%-58.4%-66.5%-40.6%6.3%-24.5%-51.7%-21.1%--
Return on assets-31.0%-24.6%-28.0%-19.9%3.3%-15.9%-41.7%-18.0%-27.9%-
Current ratio4.364.504.525.537.606.058.4915.2913.90-
Debt to equity0.160.100.00-------

Source: XBRL data Arcus Biosciences Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RCUS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RCUS$100.00M-58.3%-$453.00M-453.0%$2.69B
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$675.92B
ABBV$66.01B+10.7%$10.34B15.7%$519.48B
MRK$67.38B+4.9%$2.45B3.6%$364.98B
NVS$54.53B+8.4%$13.98B25.6%$311.52B
AZN$58.74B+8.6%$10.22B17.4%$289.61B
ABT$48.23B+10.0%$4.70B9.7%$191.31B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$180.22B

RCUS FAQ

8 questions
  • What is RCUS revenue?
    Arcus Biosciences Inc. (RCUS) reported $100.00M of revenue for the twelve months ended Sep 30, 2026. That is down 58.3% from the year before. Revenue for fiscal 2025 was $247.00M.
  • Is RCUS profitable?
    No. Arcus Biosciences Inc. reported a net loss of $453.00M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does RCUS have?
    Arcus Biosciences Inc. reported $151.00M in cash and cash equivalents and $102.00M of debt on its most recent balance sheet in SEC filings.
  • How fast is RCUS revenue growing?
    Arcus Biosciences Inc.'s revenue changed -4.3% in fiscal 2025, to $247.00M. Its compound annual growth rate was +25.9% over 5 years.
  • What is RCUS free cash flow?
    Arcus Biosciences Inc. generated -$466.00M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$465.00M less capital expenditures.
  • What is RCUS earnings per share?
    Diluted earnings per share were -$3.62 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did RCUS last report financial results?
    The latest statements here come from Arcus Biosciences Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
  • Where does this RCUS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Arcus Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.